Mylan Laboratories Limited, a active public limited company, was established on 29 November 1984 in Hyderabad, Telangana, India. Engaging in api manufacturers within the manufacturing sector, it holds CIN: U24231TG1984PLC005146. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹125.00 Cr and a paid-up capital of ₹48.70 Cr.
Formerly known as Herren Drugs P Ltd, Matrix Laboratories Limitted. It upholds a compliant status. Employing 11,193 professional, Its leadership includes Rajiv Malik (Director), Akshay Nanda (Director), Arvind Shankar Kanda (Whole-Time Director). Past directors included Fred Ehrenkranz Cohen, Kugalur Ramsesha Venkata Subrahmanian, Arun Duggal. It holds no open charges and ₹5,501.38 Cr settled loans. Its latest AGM occurred on 30 September 2025, with the balance sheet filed on 31 March 2025. It is based at Plot No.564/A/22 Road No.92 Jubilee Hills, Hyderabad, Telangana, 500096.
U24231TG1984PLC005146
005146
29 November 1984
₹125.00 Cr
₹48.70 Cr
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Mylan Laboratories Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rajiv Malik | Director | 28 Jul 2005 | Current |
| Akshay Nanda | Director | 01 Mar 2024 | Current |
| Arvind Shankar Kanda | Whole-Time Director | 28 Mar 2024 | Current |
| Ramya Suresh | Director | 25 Apr 2024 | Current |
| Sarada Kalyani Bhagawati | Cfo | 01 Nov 2014 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 25 Sep 2009 | Past |
| Pramod Abcsdd | Director | 25 Sep 2009 | Past |
| Pramod Abcsdd | Director | 08 Jan 2007 | Past |
| Pramod Abcsdd | Managing Director | 01 Jul 2008 | Past |
| Pramod Abcsdd | Additional Director | 16 Jul 2007 | Past |
| Pramod Abcsdd | Additional Director | 15 Sep 2008 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Mylan Laboratories Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 8.72% decrease. The company also saw a substantial fall in profitability, with a 25.28% decrease in profit. The company's net worth moved up by a moderate rise of 4.07%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Mylan Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹55,013,770,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Jun 2013 | Icici Bank Limited | ₹170.00 Cr | Satisfied |
| 27 Nov 2012 | Yes Bank Limited | ₹40.00 Cr | Satisfied |
| 08 Oct 2012 | Export - Import Bank Of India | ₹150.00 Cr | Satisfied |
| 18 Jul 2012 | The Ratnakar Bank Limited | ₹50.00 Cr | Satisfied |
| 10 Jul 2012 | Yes Bank Limited | ₹60.00 Cr | Satisfied |
Explore comprehensive loan charge details -
Mylan Laboratories has a workforce of 11193 employees as of Mar 25, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Mylan Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mylan Laboratories's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Progress on Mylan Laboratories Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records. was documented.
Mylan Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad. was recorded as a recent event.
Progress on Ramya Suresh was appointed as a Director was appointed as a Director on 25 Apr 2024 & has been associated with this company since 1 year 7 months . was documented.
Progress on Arvind Shankar Kanda was appointed as a Whole-time director was appointed as a Whole-time director on 28 Mar 2024 & has been associated with this company since 1 year 8 months . was documented.
Akshay Nanda was appointed as a Director was appointed as a Director on 01 Mar 2024 & has been associated with this company since 1 year 9 months . was recorded as a recent event.
The activity A charge registered on 12 Apr 2005 via Charge ID 90128817 with Andhra Bank was fully satisfied on 11 Dec 2014. was completed.
Biocon Biologics completed the $3.34-billion acquisition of U.S.-based Viatris's biosimilars business in late November .
Insulin glargine is indicated for the treatment of type 1 diabetes mellitus in adults, adolescents and children aged six years and above and type 2 diabetes mellitus in adults. .
When Biocon's partner Mylan filed for a new insulin drug, the USFDA issued a letter and four observations after inspecting one of Biocon's facilities. The letter stated that the application will not be approved in its current form. Biocon is working to fix the issues and is confident in the quality of their application. The facility also received four observations, but Biocon is confident they can address them..
The CIN of Mylan Laboratories Limited is U24231TG1984PLC005146.
Mylan Laboratories Limited is headquartered at Plot No.564/A/22 Road No.92 Jubilee Hills, Hyderabad, Telangana, 500096.
Mylan Laboratories Limited was incorporated on 29 November 1984.
The current directors of Mylan Laboratories Limited are
The primary industry of Mylan Laboratories Limited is Manufacturing.
Mylan Laboratories Limited is unlisted.
The authorized capital of Mylan Laboratories Limited is ₹125.00 Cr, and the paid-up capital is ₹48.70 Cr.
The compliance status of Mylan Laboratories Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX